COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities

The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghili, Rokhsareh, Honardoost, Maryam, Khamseh, Mohammad E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787016/
https://www.ncbi.nlm.nih.gov/pubmed/33437743
http://dx.doi.org/10.34171/mjiri.34.147
_version_ 1783632745219489792
author Aghili, Rokhsareh
Honardoost, Maryam
Khamseh, Mohammad E
author_facet Aghili, Rokhsareh
Honardoost, Maryam
Khamseh, Mohammad E
author_sort Aghili, Rokhsareh
collection PubMed
description The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.
format Online
Article
Text
id pubmed-7787016
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Iran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-77870162021-01-11 COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities Aghili, Rokhsareh Honardoost, Maryam Khamseh, Mohammad E Med J Islam Repub Iran Review Article The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities. Iran University of Medical Sciences 2020-11-02 /pmc/articles/PMC7787016/ /pubmed/33437743 http://dx.doi.org/10.34171/mjiri.34.147 Text en © 2020 Iran University of Medical Sciences http://creativecommons.org/licenses/by-nc-sa/1.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial-ShareAlike 1.0 License (CC BY-NC-SA 1.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Review Article
Aghili, Rokhsareh
Honardoost, Maryam
Khamseh, Mohammad E
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title_full COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title_fullStr COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title_full_unstemmed COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title_short COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
title_sort covid-19: case fatality and ace2 inhibitors treatment concerns in patients with comorbidities
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787016/
https://www.ncbi.nlm.nih.gov/pubmed/33437743
http://dx.doi.org/10.34171/mjiri.34.147
work_keys_str_mv AT aghilirokhsareh covid19casefatalityandace2inhibitorstreatmentconcernsinpatientswithcomorbidities
AT honardoostmaryam covid19casefatalityandace2inhibitorstreatmentconcernsinpatientswithcomorbidities
AT khamsehmohammade covid19casefatalityandace2inhibitorstreatmentconcernsinpatientswithcomorbidities

Ejemplares similares